Cargando…
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia
BACKGROUND: Approximately fifty percent of patients with acute myeloid leukemia can be cured with current therapeutic strategies which include, standard dose chemotherapy for patients at standard risk of relapse as assessed by cytogenetic and molecular analysis, or high-dose chemotherapy with alloge...
Autores principales: | Minagawa, Kentaro, Jamil, Muhammad O., AL-Obaidi, Mustafa, Pereboeva, Larisa, Salzman, Donna, Erba, Harry P., Lamb, Lawrence S., Bhatia, Ravi, Mineishi, Shin, Di Stasi, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132227/ https://www.ncbi.nlm.nih.gov/pubmed/27907031 http://dx.doi.org/10.1371/journal.pone.0166891 |
Ejemplares similares
-
Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia
por: Minagawa, Kentaro, et al.
Publicado: (2017) -
Combinatorial suicide gene strategies for the safety of cell therapies
por: Falcon, Corey, et al.
Publicado: (2022) -
Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015) -
Suicide Gene Therapy to Increase the Safety of Chimeric Antigen Receptor-Redirected T Lymphocytes
por: Casucci, Monica, et al.
Publicado: (2011) -
Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies
por: Di Stasi, Antonio, et al.
Publicado: (2015)